When Should You Get an MSA Second Opinion? What Four Years of Data Reveal

November 17, 2026

Tower MSA Partners Outcomes Report graphic on why an MSA second opinion may identify unsupported costs in an initial Medicare Set-Aside

An MSA second opinion is worth considering when the first non-Tower Medicare Set-Aside includes outdated treatment, unsupported costs, or assumptions that no longer reflect the claim. A focused clinical review can help determine whether the allocation is accurate and defensible before it delays settlement.

The first MSA may arrive higher than expected. Suddenly, the claims team needs more authority, negotiations stall, or a claim that looked ready to close faces another delay.

Sometimes the allocation is well supported. Other times, it deserves a closer look before the team treats it as a fixed settlement cost.

This is the first deep dive in Tower MSA Partners’ 2022-2025 Outcomes Report blog series. The series opener introduced six numbers that can change how claims leaders think about MSA strategy. This post starts with the decision that comes first: should the initial MSA be accepted, clarified, or reviewed again?

What four years of WCMSA data reveal about second opinions

Tower’s Outcomes Report shows that clinical intervention reduced projected MSA amounts by an annual average of 33% to 64% from 2022 through 2025. Annual MSA-related savings remained within an approximately $9 million to $12 million range.

The same report shows that Tower’s average CMS-approved WCMSA remained below the CMS national average in every year studied:

Year CMS Average Tower Average Difference
2022 $81,572 $59,051 $22,521
2023 $86,453 $78,423 $8,030
2024 $85,927 $69,867 $16,060
2025 $86,169 $67,692 $18,477

Source: Tower MSA Partners, Workers’ Compensation MSP Outcomes & Regulatory Insights Report, Section 2.3. Difference calculated from reported annual averages.

In 2025, Tower’s average CMS-approved WCMSA was $18,477 below the CMS national average. Across 100 submissions, a difference of that size would total about $1.85 million. This is a comparison of reported averages, not a measure of savings caused by Tower’s review process. The averages may reflect different claim populations and case characteristics.

These figures do not mean every first MSA is inflated, and they do not guarantee a reduction on a particular claim. They do mean the first number deserves context. If clinical facts or claim decisions are missing, outdated, or unclear, the allocation may be projecting a future that is no longer expected.

Why might an initial Medicare Set-Aside be too high?

An MSA is built from the information available at the time and a particular MSA vendor’s practices. If that information is incomplete, the projection can still be technically consistent with the record but inconsistent with the actual course of treatment. Further, an MSA vendor’s methodology or allocating errors may result in a higher MSA.

Common cost drivers include:

  • Medications that were discontinued but remain active in the records or pharmacy history
  • Treatment frequencies that no longer match the treating physician’s plan
  • Surgery, injections, or durable medical equipment that are listed as possibilities but are not currently recommended
  • Conditions or body parts that appear in the medical record but are not accepted under the workers’ compensation claim
  • Gaps in documentation that force the allocation to rely on conservative assumptions
  • Inclusion of non-Medicare covered treatment or medications
  • Misreading of the medical records

None of those issues should be removed simply because they are expensive. They should be investigated because the settlement should be based on the reasonably expected, Medicare-covered care for the compensable injury.

Four signs you should consider an MSA second opinion

  1. The treatment plan and the records do not match
    A medication may appear on an older list even though the physician stopped prescribing it. A procedure may remain in the records even after it is no longer a consideration. When the documentation tells two different stories, physician follow-up can clarify which one should drive the allocation.
  2. The MSA includes care outside the accepted claim
    Medical records often discuss multiple diagnoses and body parts. That does not automatically mean every condition belongs in the MSA. The accepted conditions, payment history, legal posture, and medical support should align before unrelated care becomes part of the settlement exposure.
  3. The allocation changes the economics of settlement
    A high MSA is not wrong merely because it exceeds settlement authority. But when the number makes settlement unworkable, a focused review can determine whether the allocation reflects unavoidable exposure or correctable assumptions. For example, will the MSA be submitted to CMS for approval or not. That distinction helps to decide.
  4. The file has not received meaningful and accurate clinical review
    A calculation can be mathematically accurate and still miss a clinical opportunity. For example, the increasing use of AI by some MSA providers, while helpful, can miss nuances that can only be known by an experienced nurse and QA team drafting an MSA report. Tower ensures that the underlying care plan is current, supported, and connected to the claim.

What an MSA second opinion should do

A useful MSA second opinion is not a generic request to make the number lower. It should test the original allocation against the medical records, pharmacy history, accepted conditions, current treatment plan, and applicable CMS guidance.

Tower’s MSA second-opinion case study shows what that can look like. An allocation prepared by another provider totaled $221,384. Tower’s review identified a medication tied to a non-accepted condition and medical treatment that was not supported for the claim. The resulting savings totaled $98,120.

That case is an example, not a promise. Its value is showing the kind of file-level discrepancies that a second opinion can uncover. The review did not start with a discount target. It started with the question: Does every projected cost belong in this claim?

These tools solve different problems:

  • An MSA second opinion reviews an allocation before submission or settlement to identify unsupported or outdated cost drivers.
  • Physician follow-up seeks current clarification from a treating provider when the medical record does not clearly state the expected care.
  • Pre-MSA triage identifies clinical and pharmacy issues before a formal MSA is prepared.
  • CMS re-review may be available after a CMS determination when the recommended value appears to result from an error and the case meets the applicable requirements.

CMS explains that WCMSA amounts are evaluated case by case. Its voluntary review process can provide finality when CMS approves the proposed amount. Review and re-review decisions should therefore be made with the current CMS WCMSA guidance and the facts of the claim in mind.

A better decision than “accept or reject”

The first MSA should not trigger an automatic challenge. It should trigger a disciplined decision.

  • Accept it when the records are current, the care is supported, the compensable conditions are clear, and the allocation fits the evidence.
  • Clarify it when a treating physician or claim document can resolve a specific uncertainty.
  • Seek an MSA second opinion when the allocation contains questionable cost drivers or materially disrupts a settlement that otherwise makes sense.
  • Use the appropriate CMS review pathway when the case requires approval, correction, or re-review.

This approach protects both sides of the decision. It avoids spending time challenging a well-supported MSA, and it avoids building settlement authority around costs that may not belong in the allocation.

How an MSA second opinion fits settlement strategy

Across a single file, a second opinion may preserve a settlement. Across a portfolio, a repeatable review process can improve reserve accuracy, reduce late-stage surprises, and help claims teams identify clinical opportunities before negotiations stall.

That is the broader lesson behind Tower’s four-year data. MSA optimization and preparation are not isolated compliance tasks. They are part of settlement strategy.

Need a closer look at the first MSA?

If an initial allocation includes questionable cost drivers or puts an otherwise workable settlement on hold, Tower MSA Partners can help assess whether an MSA second opinion is appropriate. The goal is to clarify the record and support a defensible settlement decision.

Explore Tower’s Medicare Set-Aside services and discuss a review.

The next number in the series

A lower proposal is only useful if it remains defensible. The next Outcomes Report post will examine Tower’s 76% to 88% CMS alignment index and what it reveals about the balance between preventing over-allocation and maintaining predictable CMS outcomes.

Explore the Outcomes Report series hub for the full findings and upcoming posts.

Frequently Asked Questions About Getting an MSA Second Opinion

When should I request an MSA second opinion?

Request an MSA second opinion when the first non-Tower allocation contains outdated medication, treatment not supported by current records, potentially non-compensable conditions, or a cost that stalls settlement. Start by identifying the disputed cost driver and gathering the supporting medical and claim documents.

Does a second opinion guarantee a lower MSA?

No. A second opinion may confirm that the first allocation is supported. Any change depends on the medical record, accepted conditions, current treatment plan, and applicable CMS guidance. The goal is a defensible allocation, not a predetermined reduction.

Can an MSA be changed after CMS approval?

Sometimes. CMS has defined amended-review and re-review processes, but the eligibility rules differ. Check the current CMS submission and re-review guidance before assuming an approved WCMSA can be revised.

Is the lowest MSA always the best result?

No. A supportable MSA should reflect reasonably expected Medicare-covered care related to the compensable injury. An artificially low projection can create compliance and post-settlement concerns. Clinical documentation matters more than reaching a target number.

Can I request an MSA second opinion before CMS submission?

Yes. A pre-submission second opinion can examine medication history, accepted conditions, treatment plans, and other cost drivers while there is still time to clarify the record. Learn more about Tower MSA Partners’ Medicare Set-Aside review services.

What records help determine whether an MSA is accurate?

A useful review starts with the allocation, current medical records, pharmacy history, accepted body parts and conditions, treatment recommendations, and relevant claim decisions. Compare each projected cost with the documented care expected for the compensable injury.

What benchmarks show whether an MSA is inflated?

No single national average can establish that a specific MSA is too high. Benchmarks can flag an allocation for review, but claim-specific clinical evidence, medication use, treatment frequency, and accepted conditions determine whether its assumptions are supportable.

How can a second MSA review reduce an allocation?

A review may uncover discontinued medication, unsupported procedures, or care unrelated to the accepted claim. Any adjustment should follow documented clinical clarification rather than an arbitrary discount. See Tower’s second-opinion case study for an example of how claim-specific findings can affect an allocation.

Editorial note and methodology

Tower’s Outcomes Report uses aggregated, anonymized internal outcomes from WCMSAs and related MSP services between 2022 and 2025. CMS and market benchmarks draw on CMS WCMSA statistics and related public summaries. The figures are directional benchmarks and do not guarantee results for any individual claim or portfolio. The $98,120 second-opinion example is a specific Tower case study and should not be treated as a typical or guaranteed outcome.

Sources